News - 14 Sep `20AVITA Medical: clinical trials in the USA


First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.

AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.

The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)

For more information, please contact: Elizabeth Kirshner at 661-367-9180 or